Assessment of a glycated hemoglobin point-of-care analyzer (A1CNow+) in comparison with an immunoturbidimetric method: A diagnostic accuracy study;Avaliação de um aparelho de diagnóstico local para hemoglobina glicada (A1CNow+) comparado com um método imunoturbidimétrico: Estudo de acurácia de teste diagnóstico

Sao Paulo Medical Journal

Volumn 133, Issue 6, 2015, Pages 460-464

  Affret, Aurélie ^a,b   Griz, Luiz Henrique Maciel ^b   Cesse, Eduarda Ângela Pessoa ^b,c   Specht, Yuri da Silva ^b,c   de Carvalho, Eduardo Maia Freese ^b,c   Fontbonne, Annick ^a,b  

^a UNIV MONTPELLIER   (France)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Biomedical; Diabetes mellitus; Glycosylated; Hemoglobin A; Point of care systems; Primary health care; Technology assessment

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANALYZER; ARTICLE; BLAND AND ALTMAN ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; IMMUNOASSAY; MALE; MEASUREMENT ACCURACY; POINT OF CARE TESTING; QUESTIONNAIRE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TURBIDIMETRY; BLOOD; BLOOD GLUCOSE MONITORING; DEVICES; EVALUATION STUDY; MIDDLE AGED; STANDARD; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE SELF-MONITORING; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; POINT-OF-CARE TESTING; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84954349845     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-3180.2013.9110911     Document Type: Article

References (24)

1. th ed., 2012 Update. Available from: http: //www. idf. org/sites/default/files/5E_IDFAtlasPoster_2012_EN. pdf. Accessed in 2014 (Sep 10).
2. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Secretaria de Gestão Estratégica e Participativa. Vigitel Brasil 2010: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico/Ministério da Saúde, Secretaria de Vigilância em Saúde, Secretaria de Gestão Estratégica e Participativa. Brasilia: Ministério da Saúde; 2011. Available from: http: //biavati. files. wordpress. com/2014/05/vigitel_2010. pdf. Accessed in 2014 (Sep 10).
3. Cesse EA, Carvalho EF, Souza WV, Luna CF. Tendência da mortalidade por diabetes melito no Brasil: 1950 a 2000 [Mortality trends by the diabetes mellitus in Brazil: 1950 to 2000]. Arq Bras Endocrinol Metabol. 2009; 53(6): 760-6.
4. Mattos PE, Luz LL, Santiago LM, Mattos IE. Tendência da mortalidade por diabetes melito em capitais brasileiras, 1980-2007 [Trends in mortality of diabetes mellitus patients in Brazilian capitals, 1980-2007]. Arq Bras Endocrinol Metabol. 2012; 56(1): 39-46.
5. Brasil. Portal da Saúde SUS. Cidadão, entenda o SUS. Available from: http: //portalsaude. saude. gov. br/index. php/cidadao/entenda-o-sus. Accessed in 2014 (Dec 16).
6. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Ações Programáticas Estratégicas. Plano de reorganização da atenção à hipertensão arterial e ao diabetes mellitus: hipertensão arterial e diabetes mellitus/Departamento de Ações Programáticas Estratégicas. Brasilia: Ministério da Saúde; 2001. Available from: http: //bvsms. saude. gov. br/bvs/publicacoes/miolo2002. pdf. Accessed in 2014 (Sep 10).
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329(14): 977-86.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837-53.
9. American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010; 33 Suppl 1: S11-61.
10. National Glycohemoglobin Standardization Program. Harmonizing Hemoglobin A1c Testing. More About HbA1c. Clinical use. Available from: http: //www. ngsp. org/ADA. asp. Accessed in 2014 (Sep 11).
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476): 307-10.
12. Price CP. Point of care testing. BMJ. 2001; 322(7297): 1285-8.
13. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999; 22(11): 1785-9.
14. Miller CD, Barnes CS, Phillips LS, et al. Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care. 2003; 26(4): 1158-63.
15. Gialamas A, St John A, Laurence CO, Bubner TK; PoCT Management Committee. Point-of-care testing for patients with diabetes, hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review. Fam Pract. 2010; 27(1): 17-24.
16. Yager P, Domingo GJ, Gerdes J. Point-of-care diagnostics for global health. Annu Rev Biomed Eng. 2008; 10: 107-44.
17. Martin DD, Shephard MD, Freeman H, et al. Point-of-care testing of HbA1c and blood glucose in a remote Aboriginal Australian community. Med J Aust. 2005; 182(10): 524-7.
18. Martin CL. Quality control issues in point of care testing. Clin Biochem Rev. 2008; 29 Suppl 1: S79-82.
19. Bode BW, Irvin BR, Pierce JA, Allen M, Clark AL. Advances in hemoglobin A1c point of care technology. J Diabetes Sci Technol. 2007; 1(3): 405-11.
20. Little RR, Lenters-Westra E, Rohlfing CL, Slingerland R. Point-of-care assays for hemoglobin A(1c): is performance adequate? Clin Chem. 2011; 57(9): 1333-4.
21. Sacks DB, Arnold M, Bakris GL, et al. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011; 57(6): 793-8.
22. Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2010; 56(1): 44-52.
23. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002; 48(3): 436-72.
24. Arrendale JR, Cherian SE, Zineh I, Chirico MJ, Taylor JR. Assessment of glycated hemoglobin using A1CNow+ point-of-care device as compared to central laboratory testing. J Diabetes Sci Technol. 2008; 2(5): 822-7.